It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

Having a prostate-specific antigen (PSA) test result above 4.0 ng/mL is considered abnormal and it is worth closer testing, a physician said yesterday, as he suggested individuals with a family ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, ...

Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.

NEW YORK (Reuters Health) - Hypoxia, or reduced oxygen levels, in prostate tumors significantly predicts a poor long-term biochemical outcome, regardless of other prognostic factors, such as tumor ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...